

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. **(Currently Amended)** A method of inhibiting the activity of a G1 cdk, comprising contacting said cdk with a substance which is selected from the group consisting of: ~~a peptide fragment of 40 amino acids or less of p21, a derivative thereof, the peptide fragment or derivative thereof coupled to a non-peptidyl coupling partner and the peptide fragment or derivative thereof coupled to a non-p21 peptide sequence;~~

(i) a peptide fragment of 40 amino acids or less of p21;

(ii) a derivative of the peptide fragment of (i);

(iii) the peptide fragment of (i) coupled to a non-peptidyl coupling partner;

(iv) the derivative of (ii) coupled to a non-peptidyl coupling partner;

(v) the peptide fragment of (i) coupled to a non-p21 peptide sequence; and

(vi) the derivative of (ii) coupled to a non-p21 peptide sequence;

wherein the peptide fragment of (i) or the derivative of (ii) comprises comprising the motif:



wherein

(a) x comprises any amino acid;

(b) y and z comprise hydrophobic amino acids;

(c) K is present, deleted or replaced by another amino acid; and

(d) P is present, deleted or replaced by another amino acid.

2. **(Previously Presented)** The method according to claim 1 wherein at least one of y or z comprises an amino acid selected from the group consisting of alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan and methionine.

3. **(Previously Presented)** The method according to claim 1, wherein said substance consists of the peptide fragment of 40 amino acids or less of p21 or an active portion or derivative thereof.

4. **(Previously Presented)** The method according to claim 1, wherein said peptide fragment consists of residues 16-35 of the p21<sup>WAF1</sup> amino acid sequence or an active portion or derivative thereof.
5. **(Previously Presented)** The method according to claim 3 or 4, wherein said active portion or derivative has at least 80% identity over at least 5 amino acids of p21.
6. **(Withdrawn)** The method according to claim 1 wherein said substance is the peptide fragment or derivative thereof coupled to a non-p21 peptide sequence.
7. **(Withdrawn)** The method according to claim 6, wherein the non-p21 peptide sequence has the sequence RQIKIWFQNRRMKWKK.
8. **(Previously Presented)** The method according to claim 1 wherein the peptide fragment binds to a G1 cyclin or a G1 cdk.
- 9-10. **(Cancelled)**
11. **(Previously Presented)** The method according to claim 1 wherein the cdk activity comprises Rb phosphorylation.
12. **(Previously Presented)** The method according to claim 1 wherein cell cycle arrest is induced.
13. **(Withdrawn)** The method according to claim 1, wherein said substance is the peptide fragment or derivative thereof coupled to a non-peptidyl coupling partner.